Вакцинация против гриппа и прогноз пациентов с высоким сердечно-сосудистым риском

Дмитриева О.А., Миронова О.Ю., Фомин В.В. Вакцинация против гриппа и прогноз пациентов с высоким сердечно-сосудистым риском. Терапевтический архив. 2021; 93 (9): 1100–1105. DOI: 10.26442/00403660.2021.09.201023

________________________________________________

Dmitrieva OA, Mironova OIu, Fomin VV. Influenza vaccination and prognosis for patients with high cardiovascular risk. Terapevticheskii Arkhiv (Ter. Arkh.). 2021; 93 (9): 1100–1105. DOI: 10.26442/00403660.2021.09.201023

Читать PDF

Аннотация

Сердечно-сосудистые и респираторные заболевания занимают одни из лидирующих позиций среди причин смертности населения в мире более 15 лет. По результатам разных исследований выявлена четкая взаимосвязь между заболеваемостью гриппом и декомпенсацией сердечно-сосудистых заболеваний, что ведет к развитию острого коронарного синдрома, острой сердечной недостаточности и инфаркта миокарда. Также заболеваемость гриппом связана с увеличением продолжительности госпитализации, расходов на лечение и смертности пациентов. Вакцинация против гриппа, особенно у пациентов с высоким сердечно-сосудистым риском, является одной из важнейших мер вторичной профилактики. Статья посвящена обзору проблем вакцинации против гриппа, изучению прогноза пациентов с высоким сердечно-сосудистым риском, а также общим моментам в патогенезе гриппа и сердечно-сосудистых заболеваний.

Ключевые слова: сердечно-сосудистые заболевания, грипп, сердечно-сосудистый риск, острый коронарный синдром, инфаркт миокарда, вакцинация против гриппа

________________________________________________

Cardiovascular and respiratory diseases have been one of the leading causes of mortality in the world for over 15 years. According to the results of various studies, a clear connection was revealed between the incidence of influenza and the decompensation of cardiovascular diseases, which leads to the development of acute coronary syndrome, acute heart failure and myocardial infarction. Also, the incidence of influenza is associated with an increase in the length of hospitalization, treatment costs and patient mortality. Influenza vaccination, especially in patients with high cardiovascular risk, is one of the most important secondary prevention measures. The article is dedicated to an overview of the problems of vaccination against influenza, the study of the prognosis of patients with high cardiovascular risk, as well as general points in the pathogenesis of influenza and cardiovascular diseases.

Keywords: cardiovascular diseases, influenza, cardiovascular risk, acute coronary syndrome, myocardial infarction, influenza vaccination

Полный текст

Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Warren-Gash C, Blackburn R, Whitaker H, et al. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. Eur Respir J. 2018;51(3):1701794. DOI:10.1183/13993003.01794-2017
2. Graham-Rowe D. Epidemiology: Racing against the flu. Nature. 2011;480(7376):S2-3. DOI:10.1038/480S2a
3. Vardeny O, Udell JA, Joseph J, et al. High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. Am Heart J. 2018;202:97-103. DOI:10.1016/j.ahj.2018.05.007
4. For Europe WHORO. WHO Regional Office for Europe recommendations on influenza vaccination for the 2020/2021 season during the ongoing COVID-19 pandemic. World Health Organization. Regional Office for Europe; 2020.
5. Клинические рекомендации. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. 2020. Режим доступа: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_OKS_sST.pdf. Ссылка активна на 24.08.2021 [Clinical guidelines. Acute myocardial infarction with ST segment elevation on electrocardiogram. 2020. Available at: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_OKS_sST.pdf. Accessed: 24.08.2021 (in Russian)].
6. Клинические рекомендации. Острый инфаркт миокарда без подъема сегмента ST электрокардиограммы. 2020. Режим доступа: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_OKS_bST.pdf. Ссылка активна на 24.08.2021 [Clinical guidelines. Acute myocardial infarction without ST segment elevation on electrocardiogram. 2020. Available at: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_OKS_bST.pdf. Accessed: 24.08.2021 (in Russian)].
7. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-367. DOI:10.1093/eurheartj/ehaa575
8. Ciszewski A. Cardioprotective effect of influenza and pneumococcal vaccination in patients with cardiovascular diseases. Vaccine. 2018;36:202-6. DOI:10.1016/j.vaccine.2017.11.078
9. Muscente F, de Caterina R. Causal relationship between influenza infection and risk of acute myocardial infarction: pathophysiological hypothesis and clinical implications. Eur Heart J. 2020;22(Suppl. E): E68-72. DOI:10.1093/EURHEARTJ/SUAA064
10. Luan YY, Yao YM. The clinical significance and potential role of C-reactive protein in chronic inflammatory and neurodegenerative diseases. Front Immunol. 2018;9:1-8. DOI:10.3389/fimmu.2018.01302
11. Garraud O, Kehrel BE, Badimon L, et al. C-Reactive Protein in Atherothrombosis and Angiogenesis. Frontiers in Immunology. Frontiers Media S.A. 2018;9:430. DOI:10.3389/fimmu.2018.00430
12. Tripathi B, Kumar V, Kalra A, et al. Influence of Influenza Infection on In-Hospital Acute Myocardial Infarction Outcomes. Am J Cardiol. 2020;130:7-14. DOI:10.1016/j.amjcard.2020.05.045
13. Cardoso R, Rivera M, Czarny MJ, et al. In-Hospital Management and Outcomes of Patients With Acute Myocardial Infarction and Influenza. Am J Cardiol. 2020;125(6):840-4. DOI:10.1016/j.amjcard.2019.12.032
14. Smeeth L, Thomas SL, Hall AJ, et al. Risk of Myocardial Infarction and Stroke after Acute Infection or Vaccination. N Engl J Med. 2004;351(25):2611-8. DOI:10.1056/nejmoa041747
15. Gurfinkel EP, Leon De La Fuente R, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study: One-year follow-up. Eur Heart J. 2004;25(1):25-31. DOI:10.1016/j.ehj.2003.10.018
16. Naghavi M, Barlas Z, Siadaty S, et al. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation. 2000;102(25):3039-45.
DOI:10.1161/01.CIR.102.25.3039
17. Meyers DG, Beahm DD, Jurisich PD, et al. Influenza and pneumococcal vaccinations fail to prevent myocardial infarction. Heart Drug. 2004;4(2):96-100. DOI:10.1159/000077705
18. Heffelfinger JD, Heckbert SR, Psaty BM, et al. Influenza vaccination and risk of incident myocardial infarction. Hum Vaccin. 2006;2(4):161-6. DOI:10.4161/hv.2.4.2943
19. Puig-Barberà J, Díez-Domingo J, Varea ÁB, et al. Effectiveness of MF59TM-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine. 2007;25(42):7313-21. DOI:10.1016/j.vaccine.2007.08.039
20. Siriwardena AN, Gwini SM, Coupland CAC. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: Matched case – Control study. CMAJ. 2010;182(15):1617-23. DOI:10.1503/cmaj.091891
21. Warren-Gash C, Geretti AM, Hamilton G, et al. Influenza-like illness in acute myocardial infarction patients during the winter wave of the influenza A H1N1 pandemic in London: A case-control study. BMJ Open. 2013;3(5):1-7. DOI:10.1136/bmjopen-2013-002604
22. MacIntyre CR, Heywood AE, Kovoor P, et al. Ischaemic heart disease, influenza and influenza vaccination: A prospective case control study. Heart. 2013;99(24):1843-8. DOI:10.1136/heartjnl-2013-304320
23. Hsu SY, Chen FL, Liaw YP, et al. A matched influenza vaccine strain was effective in reducing the risk of acute myocardial infarction in elderly persons: A population-based study. Med (United States). 2016;95(10):1-6. DOI:10.1097/MD.0000000000002869
24. Barnes M, Heywood AE, Mahimbo A, et al. Acute myocardial infarction and influenza: A meta-analysis of case-control studies. Heart. 2015;101(21):1738-47. DOI:10.1136/heartjnl-2015-307691
25. Karaulov AV, Bykov AS, Volkova NV. Review of Grippol Family Vaccine Studies and Modern Adjuvant Development. Epidemiol Vaccinal Prev. 2019;18(4):101-19.
DOI:10.31631/2073-3046-2019-18-4-101-119
26. Wu HH, Chang YY, Kuo SC, Chen YT. Influenza vaccination and secondary prevention of cardiovascular disease among Taiwanese elders – A propensity score-matched follow-up study. PLoS One. 2019;14(7):e0219172. DOI:10.1371/journal.pone.0219172
27. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to Lipid-lowering Therapy and the Use of Preventive Health Services: An Investigation of the Healthy User Effect. Am J Epidemiol. 2007;166(3):348-54. DOI:10.1093/aje/kwm070
28. Shrank WH, Patrick AR, Brookhart MA. Healthy User and Related Biases in Observational Studies of Preventive Interventions: A Primer for Physicians. J Gen Intern Med. 2010;26(5):546-50. DOI:10.1007/s11606-010-1609-1
29. Madjid M, Awan I, Ali M, et al. Influenza and atherosclerosis: Vaccination for cardiovascular disease prevention. Expert Opin Biol Ther. 2005;5(1):91-6. DOI:10.1517/14712598.5.1.91
30. Shah AM, Pfeffer MA, Hartley LH, et al. Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction. Am J Cardiol. 2010;106(7):911-6. DOI:10.1016/j.amjcard.2010.05.021
31. Critchley JA, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2012;(2):1465-858. DOI:10.1002/14651858.CD003041.pub3
32. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81. DOI:10.1016/S0140-6736(10)61350-5
33. Sheng X, Wei L, Murphy MJ, MacDonald TM. Statins and total (not LDL) cholesterol concentration and outcome of myocardial infarction: Results from a meta-analysis and an observational study. Eur J Clin Pharmacol. 2009;65(11):1071-80.
DOI:10.1007/s00228-009-0720-x
34. Ferrari R, Bertrand ME, Remme WJ, et al. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: The EUROPA trial. Expert Rev Cardiovasc Ther. 2007;5(6):1037-46. DOI:10.1586/14779072.5.6.1037
35. England TN. Effect of Ramipril on Cardiovascular Events in High-Risk Patients. N Engl J Med. 2000;343(1):64-6. DOI:10.1056/nejm200007063430113
36. MacIntyre CR, Mahimbo A, Moa AM, Barnes M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart. 2016;102(24):1953-6. DOI:10.1136/heartjnl-2016-309983
37. Shalnova SA, Deev AD. Russian mortality trends in the early XXI century: Official statistics data. Cardiovasc Ther Prev. 2011;10(6):5-10. DOI:10.15829/1728-8800-2011-6-5-10
38. Goldsteyn EM. Influenza-associated mortality for circulatory and respiratory causes during the 2013–2014 through the 2018–2019 influenza seasons in Russia. Int J Appl Fundam Res. 2019;12:9-16. DOI:10.17513/mjpfi.12945
39. Vardeny O, Madjid M, Solomon SD. Applying the Lessons of Influenza to COVID-19 During a Time of Uncertainty. Circulation. 2020;141(21):1667-9. DOI:10.1161/CIRCULATIONAHA.120.046837

________________________________________________

1. Warren-Gash C, Blackburn R, Whitaker H, et al. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. Eur Respir J. 2018;51(3):1701794. DOI:10.1183/13993003.01794-2017
2. Graham-Rowe D. Epidemiology: Racing against the flu. Nature. 2011;480(7376):S2-3. DOI:10.1038/480S2a
3. Vardeny O, Udell JA, Joseph J, et al. High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. Am Heart J. 2018;202:97-103. DOI:10.1016/j.ahj.2018.05.007
4. For Europe WHORO. WHO Regional Office for Europe recommendations on influenza vaccination for the 2020/2021 season during the ongoing COVID-19 pandemic. World Health Organization. Regional Office for Europe; 2020.
5. Clinical guidelines. Acute myocardial infarction with ST segment elevation on electrocardiogram. 2020. Available at: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_OKS_sST.pdf. Accessed: 24.08.2021 (in Russian).
6. Clinical guidelines. Acute myocardial infarction without ST segment elevation on electrocardiogram. 2020. Available at: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_OKS_bST.pdf. Accessed: 24.08.2021 (in Russian).
7. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-367. DOI:10.1093/eurheartj/ehaa575
8. Ciszewski A. Cardioprotective effect of influenza and pneumococcal vaccination in patients with cardiovascular diseases. Vaccine. 2018;36:202-6. DOI:10.1016/j.vaccine.2017.11.078
9. Muscente F, de Caterina R. Causal relationship between influenza infection and risk of acute myocardial infarction: pathophysiological hypothesis and clinical implications. Eur Heart J. 2020;22(Suppl. E): E68-72. DOI:10.1093/EURHEARTJ/SUAA064
10. Luan YY, Yao YM. The clinical significance and potential role of C-reactive protein in chronic inflammatory and neurodegenerative diseases. Front Immunol. 2018;9:1-8. DOI:10.3389/fimmu.2018.01302
11. Garraud O, Kehrel BE, Badimon L, et al. C-Reactive Protein in Atherothrombosis and Angiogenesis. Frontiers in Immunology. Frontiers Media S.A. 2018;9:430. DOI:10.3389/fimmu.2018.00430
12. Tripathi B, Kumar V, Kalra A, et al. Influence of Influenza Infection on In-Hospital Acute Myocardial Infarction Outcomes. Am J Cardiol. 2020;130:7-14. DOI:10.1016/j.amjcard.2020.05.045
13. Cardoso R, Rivera M, Czarny MJ, et al. In-Hospital Management and Outcomes of Patients With Acute Myocardial Infarction and Influenza. Am J Cardiol. 2020;125(6):840-4. DOI:10.1016/j.amjcard.2019.12.032
14. Smeeth L, Thomas SL, Hall AJ, et al. Risk of Myocardial Infarction and Stroke after Acute Infection or Vaccination. N Engl J Med. 2004;351(25):2611-8. DOI:10.1056/nejmoa041747
15. Gurfinkel EP, Leon De La Fuente R, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study: One-year follow-up. Eur Heart J. 2004;25(1):25-31. DOI:10.1016/j.ehj.2003.10.018
16. Naghavi M, Barlas Z, Siadaty S, et al. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation. 2000;102(25):3039-45.
DOI:10.1161/01.CIR.102.25.3039
17. Meyers DG, Beahm DD, Jurisich PD, et al. Influenza and pneumococcal vaccinations fail to prevent myocardial infarction. Heart Drug. 2004;4(2):96-100. DOI:10.1159/000077705
18. Heffelfinger JD, Heckbert SR, Psaty BM, et al. Influenza vaccination and risk of incident myocardial infarction. Hum Vaccin. 2006;2(4):161-6. DOI:10.4161/hv.2.4.2943
19. Puig-Barberà J, Díez-Domingo J, Varea ÁB, et al. Effectiveness of MF59TM-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine. 2007;25(42):7313-21. DOI:10.1016/j.vaccine.2007.08.039
20. Siriwardena AN, Gwini SM, Coupland CAC. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: Matched case – Control study. CMAJ. 2010;182(15):1617-23. DOI:10.1503/cmaj.091891
21. Warren-Gash C, Geretti AM, Hamilton G, et al. Influenza-like illness in acute myocardial infarction patients during the winter wave of the influenza A H1N1 pandemic in London: A case-control study. BMJ Open. 2013;3(5):1-7. DOI:10.1136/bmjopen-2013-002604
22. MacIntyre CR, Heywood AE, Kovoor P, et al. Ischaemic heart disease, influenza and influenza vaccination: A prospective case control study. Heart. 2013;99(24):1843-8. DOI:10.1136/heartjnl-2013-304320
23. Hsu SY, Chen FL, Liaw YP, et al. A matched influenza vaccine strain was effective in reducing the risk of acute myocardial infarction in elderly persons: A population-based study. Med (United States). 2016;95(10):1-6. DOI:10.1097/MD.0000000000002869
24. Barnes M, Heywood AE, Mahimbo A, et al. Acute myocardial infarction and influenza: A meta-analysis of case-control studies. Heart. 2015;101(21):1738-47. DOI:10.1136/heartjnl-2015-307691
25. Karaulov AV, Bykov AS, Volkova NV. Review of Grippol Family Vaccine Studies and Modern Adjuvant Development. Epidemiol Vaccinal Prev. 2019;18(4):101-19.
DOI:10.31631/2073-3046-2019-18-4-101-119
26. Wu HH, Chang YY, Kuo SC, Chen YT. Influenza vaccination and secondary prevention of cardiovascular disease among Taiwanese elders – A propensity score-matched follow-up study. PLoS One. 2019;14(7):e0219172. DOI:10.1371/journal.pone.0219172
27. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to Lipid-lowering Therapy and the Use of Preventive Health Services: An Investigation of the Healthy User Effect. Am J Epidemiol. 2007;166(3):348-54. DOI:10.1093/aje/kwm070
28. Shrank WH, Patrick AR, Brookhart MA. Healthy User and Related Biases in Observational Studies of Preventive Interventions: A Primer for Physicians. J Gen Intern Med. 2010;26(5):546-50. DOI:10.1007/s11606-010-1609-1
29. Madjid M, Awan I, Ali M, et al. Influenza and atherosclerosis: Vaccination for cardiovascular disease prevention. Expert Opin Biol Ther. 2005;5(1):91-6. DOI:10.1517/14712598.5.1.91
30. Shah AM, Pfeffer MA, Hartley LH, et al. Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction. Am J Cardiol. 2010;106(7):911-6. DOI:10.1016/j.amjcard.2010.05.021
31. Critchley JA, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2012;(2):1465-858. DOI:10.1002/14651858.CD003041.pub3
32. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81. DOI:10.1016/S0140-6736(10)61350-5
33. Sheng X, Wei L, Murphy MJ, MacDonald TM. Statins and total (not LDL) cholesterol concentration and outcome of myocardial infarction: Results from a meta-analysis and an observational study. Eur J Clin Pharmacol. 2009;65(11):1071-80.
DOI:10.1007/s00228-009-0720-x
34. Ferrari R, Bertrand ME, Remme WJ, et al. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: The EUROPA trial. Expert Rev Cardiovasc Ther. 2007;5(6):1037-46. DOI:10.1586/14779072.5.6.1037
35. England TN. Effect of Ramipril on Cardiovascular Events in High-Risk Patients. N Engl J Med. 2000;343(1):64-6. DOI:10.1056/nejm200007063430113
36. MacIntyre CR, Mahimbo A, Moa AM, Barnes M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart. 2016;102(24):1953-6. DOI:10.1136/heartjnl-2016-309983
37. Shalnova SA, Deev AD. Russian mortality trends in the early XXI century: Official statistics data. Cardiovasc Ther Prev. 2011;10(6):5-10. DOI:10.15829/1728-8800-2011-6-5-10
38. Goldsteyn EM. Influenza-associated mortality for circulatory and respiratory causes during the 2013–2014 through the 2018–2019 influenza seasons in Russia. Int J Appl Fundam Res. 2019;12:9-16. DOI:10.17513/mjpfi.12945
39. Vardeny O, Madjid M, Solomon SD. Applying the Lessons of Influenza to COVID-19 During a Time of Uncertainty. Circulation. 2020;141(21):1667-9. DOI:10.1161/CIRCULATIONAHA.120.046837

Авторы

О.А. Дмитриева*, О.Ю. Миронова, В.В. Фомин

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*olga.dm.ru@mail.ru

________________________________________________

Olga A. Dmitrieva*, Olga Iu. Mironova, Victor V. Fomin

Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*olga.dm.ru@mail.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.